Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

NCT04638270 | Unknown Early Phase 1

• 1 other identifier: FasT CAR-T for NHL
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. To make a further improvement, adapting the FasT CAR-T cells manufacture technology to shorten the manufacturing time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 targeted CAR-T cell therapy.

Conditions

Lymphoma, Non-Hodgkin

Outcome Measures

Primary Outcomes (3)

• The measurable lesion size

  The anti-tumor efficiency of FasT CD19 targeted CAR-T cells

  4 weeks after infusion

• The standardized uptake value

  The anti-tumor efficiency of FasT CD19 targeted CAR-T cells

  4 weeks after infusion

• treatment-related adverse events as assessed by CTCAE v5.0

  The safey evaluation of FasT CD19 targeted CAR-T cells

  within 4 weeks after infusion

Secondary Outcomes (2)

• The measurable lesion size

  3, 6, 12 and 24 months after infusion

• The standardized uptake value

  3, 6, 12 and 24 months after infusion

Study Arms (1)

anti-CD19 FasT CAR-T

EXPERIMENTAL

The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the "3 + 3" dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage. 3×10\^5 /KG 6×10\^5 /KG 1×10\^6/KG

Biological: anti-CD19 FasT CAR-T cells

Interventions

anti-CD19 FasT CAR-T cells BIOLOGICAL

Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.

anti-CD19 FasT CAR-T

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects between the ages of 18 and 70（including critical values）；
• Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) ：
• Refractory B-NHL ：Subjects of which the best response to standard first-line treatment is PD,(those intolerant to first-line treatment will not be included in this study). Subjects of which the best response to at least four courses of first-line treatment is SD, with a duration of SD less than 6 months after the last treatment. Subjects of which the best response to the last course of second-line treatment or above treatments is PD or the best response to at least two courses of second-line treatment or above treatments is SD, with a duration of SD less than 6 months.
• Male or female subjects between the ages of 18 and 70（including critical values）； Subjects histologically confirmed as diffuse diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), primary mediastinal B cell lymphoma (PMBCL) and mantle cell lymphoma (MCL) ：
• Refractory B-NHL ：Subjects of which the best response to standard first-line treatment is PD,(those intolerant to first-line treatment will not be included in this study). Subjects of which the best response to at least four courses of first-line treatment is SD, with a duration of SD less than 6 months after the last treatment. Subjects of which the best response to the last course of second-line treatment or above treatments is PD or the best response to at least two courses of second-line treatment or above treatments is SD, with a duration of SD less than 6 months.
• Relapsed B-NHL：The disease relapses confirmed by histopathology in subjects who achieved complete remission after standard systematic treatment and second-line treatment. Or the disease relapses confirmed by histopathology within 1 year after hematopoietic stem cell transplantation (not limited to the previous therapeutic regimen) ； Subjects with TFL must receive chemotherapy before transformation and meet the above definition of relapse or refractory after transformation.
• According to Lugano response criteria 2014, there should be at least one evaluable tumor focus: the longest diameter of intranodal focus \> 1.5cm, the longest diameter of extranodal focus \> 1.0cm； Positive expression of CD19 in tumor tissue； Subjects who have no effect or relapse after single-target CAR-T treatment can also be included in the group.
• Approved anti-tumor therapies, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 2 weeks before the precondition.
• ECOG≤1； Life expectancy ≥ 3 months； Neutrophil absolute count ≥ 1×10\^9/L； platelet count ≥ 50×10\^9/L； Absolute lymphocyte count ≥ 1×10\^8/L ；
• Adequate organ function reserve :
• GPT, GST ≤ 2.5× UNL（upper normal limit）； Creatinine clearance (Cockcroft Gault method）≥60mL/min； Serum total bilirubin ≤1.5× UNL； The left ventricular ejection fraction (LVEF) ≥ 50% was diagnosed by echocardiography, and there was no clinically significant pericardial effusion and ECG abnormality； Basic oxygen saturation in indoor natural air environment \> 92%； It can establish the venous access needed for collection without the contraindications of leukocyte collection； For female subjects of childbearing age, results are negative in urine pregnancy test before screening and administration, and subjects agree to take effective contraceptive measures at least one year after infusion; Male subjects with partners' fertility must agree to use effective barrier contraceptive methods at least one year after infusion, and avoid sperm donation； Voluntary signing of informed consent;

You may not qualify if:

• Any of the following points shall be deemed as no entry into this study：
• Other tumors except cured non-melanoma skin cancer, cervical cancer in situ, superficial bladder cancer, breast duct cancer in situ, or other malignant tumors with complete remission of more than 5 years)；
• Severe mental disorders；
• A history of genetic diseases such as Fanconi anemia, Shudder-Dale syndrome, Costman syndrome, or any other known bone marrow failure syndrome； History of allogeneic stem cell transplantation；
• Heart disease with grade III-IV heart failure \[NYHA classification\], myocardial infarction, angioplasty or stenting, unstable angina or other heart diseases with prominent clinical symptoms within one year before admission；
• Subjects with any indwelling catheter or drainage tube (such as percutaneous nephrostomy tube, bile drainage tube or pleura/peritoneum/pericardium catheter), should be excluded. (Special central venous catheter is allowed)；
• Subjects with a history of CNS lymphoma, CSF malignant cells, or brain metastasis；
• Subjects with a history of CNS disease, such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS；
• Any of the following virological ELISA results are positive: HIV antibody, HCV antibody, TPPA, HBsAg；
• Active infection requiring systematic treatment within 2 weeks before single collection；
• Subjects with known severe allergic reactions to cyclophosphamide or fludarabine, or diagnosed as the allergy；
• History of autoimmune diseases (e.g. Crohn disease, rheumatoid arthritis, systemic lupus erythematosus) that cause end-organ damage or require systemic immunosuppressive medications or systemic disease modifying drugs in the past 2 years；
• Presence of pulmonary fibrosis；
• Subjects who have received other clinical trial treatment within 4 weeks before participating in this trial should be excluded. Or the signing date of informed consent is within 5 half-lives of the last application of another clinical trial (whichever is longer)；
• Subjects with poor compliance due to physiological, family, social, geographical and other factors, or those unable to cooperate with the study plan or follow-up； At the discretion of the investigator, there are complications requiring systemic corticosteroid therapy (≥ 5mg / day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive drugs within 6 months after this clinical research treatment；

Sponsors & Collaborators

• Xinqiao Hospital of Chongqing: lead
• Gracell Biotechnologies (Shanghai) Co., Ltd.: collaborator
• 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China: collaborator
• The Second Affiliated Hospital of Chongqing Medical University: collaborator
• The Affiliated Hospital Of Guizhou Medical University: collaborator
• The Second Affiliated Hospital of Kunming Medical University: collaborator
• Chongqing University Cancer Hospital: collaborator

Study Sites (1)

Department of Hematology, Xinqiao Hospital

Chongqing, Chongqing Municipality, 400037, China

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Xi Zhang, MD phD

CONTACT

13808310064; zhangxxi@sina.com

Ruihao Huang

CONTACT

+86 18984398751; 1169731117@qq.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chef of Hematology Department

Study Record Dates

• First Submitted: November 13, 2020
• First Posted: November 20, 2020
• Study Start: November 21, 2020
• Primary Completion: November 1, 2021
• Study Completion: November 1, 2023
• Last Updated: November 20, 2020

Record last verified: 2020-11

Locations

CN (1)